Copper 64-DOTA-TLX 592

N/A

Report date: 2025/09/24 16:01:08

Base Information

Drug NameCopper 64-DOTA-TLX 592

Drug Alias Name64Cu-TLX-59264Cu-DOTA-TLX592

ClassificationRadiation-emitting products > Radioactive diagnostic agentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedRadiation-emitting products > Nuclides > Copper > 64Cu +[4]

Mechanisms of ActionPositron-emission tomography enhancersRadionuclide imaging enhancersProstate-Specific Membrane Antigen modulators

TargetsProstate-Specific Membrane Antigen

Therapy Area/IndicationsProstatic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryAustralia

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesTelix International Pty Ltd

China Registration ClassN/A

Develop Information

Active CompaniesTelix Pharmaceuticals (Innovations) Pty Ltd

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A